Merck Serono Tops BMI's Pharmaceutical Research Investment Index For Second Quarter Running

Compared with a selection of 16 other pharmaceutical and healthcare companies, Merck Serono spends the greatest proportion of its sales on research and development (R&D), according to BMI's Pharmaceutical Research Investment Index (PRII) for Q210.

To read the full article, please choose one of the following options: